Key Word Submission Number(s)

(2R,6R)-hydroxynorketamine P354

(R,S)-ketamine P250, P354, P365, P726

(R,S)-ketamine infusion therapy P335

11β-hydroxylase inhibitor P148

17-β-estradiol P197, P314

22q11 51

22q11 deletion syndrome 51.4, P75, P516, P568, P573

22q11.2 CNV P539

22q11.2 deletion syndrome P487

2-AG 56.4, P88, P559

2-photon techniques P751

3-hydroxykynurenine P579

5-HT P83, P265

5-HT1A receptors P607

5-ht1b 52.3

5-HT2A receptor P360, P459

5-HT2A receptors P405

5-HT4 receptor P81

7 Tesla fMRI P534

7T fMRI P429

7T MRS P64, P185, P283, P534

a4b2 nicotinic acetylcholine receptors P673

ABCD P141, P511

ABCD study P34, P136, P139, P162, P290

Abstinence P669

Abuse Liability P693

academic performance P139

acamprosate P681

accelerated aging P217

acetylcholine 1.5, 51, 51.3, P107, P381, P573

Acid-sensing P71

acoustic startle P568

acoustic startle response P474

Active Avoidance 56, 56.2, 56.4

Acute and Chronic Stress 34, P14, P86, P278, P483, P747

Acute dose P454

Acute Stress 31.2, 34.1, 34.4, P15, P66, P445, P630, P642, P666

Acute Traumatic Stress P59, P410

Acyl chain remodeling P300

Adaptive Behavior P206

Adaptive deep brain stimulation P235

addiction 9, 55.1, P56, P586, P643, P649, P670, P675, P723, P738

addiction circuitry P731, P732

Addictions Neuroclinical Assessment P658

ADHD 30, 30.1, 30.2, 44, 44.1, P119, P123, P158, P167, P173, P175, P291, P293, P424, P433, P443

adjunctive P343

Adjunctive cariprazine P436

Adolescence 21.1, P42, P78, P135, P139, P160, P178, P189, P190, P239, P280, P299, P626, P660

Adolescence- Critical Period 43.1, 57, 57.1, 57.4, P706

Adolescent P168, P705, P723

Adolescent Alcohol P49, P632, P647

Adolescent Alcohol Use P741

Adolescent Anxiety 38, 49.2, P113, P290

Adolescent brain P115

Adolescent Brain and Cognitive Development Study P121

Adolescent Brain Cognitive Development study P124, P161, P302

adolescent cannabis P517

Adolescent Depression 49.2, 57, P165, P252, P290

adolescent development P129

Adolescent PTSD P57

adolescent stress P575

Adolescents P236, P295

adult hippocampal neurogenesis P9, P382

Adult stem cells P392

Adverse childhood events P161, P296

Adverse life experiences P312

affective behavior 40.4, P388

affective components of pain P623

affective disorders P305

affective instability P32

African American P160, P522

Age of Onset P520

agency 43.4

Aggression P94, P101, P341, P390

Aging 14, 14.4, 18.3, P1, P5, P10, P14, P283, P437, P570, P657

AK-1402 P366

akathisia P351

Akt P481

Alcohol 50, P4, P444, P621, P626, P627, P631, P641, P646, P654, P655, P666, P672, P684, P692, P694, P710, P715, P721, P729, P730, P736

Alcohol Abstinence P725, P737

alcohol abuse P184, P610

Alcohol and substance use disorders P596, P606, P638, P720

Alcohol consumption P651

Alcohol dependence P751

alcohol drinking P688

Alcohol epigenetic marks P610

Alcohol Response P656

Alcohol Sensitivity P686, P691

alcohol use disorder 25.2, 52.4, P182, P588, P613, P622, P629, P630, P645, P651, P656, P667, P671, P678, P679

Alcohol Use Disorder - Treatment 50.3, P608, P614, P625, P643, P669, P681, P688

Alcohol use disorder and drug addiction 25, 34.4, P595

alcohol use disorders 25.3, P154

alcohol withdrawal P71, P612

allopregnanolone P311

allostatic load P164

Allosteric modulator P601

alpha 7 nAchR P540

alternative splicing P153

altruism P429

Alzheimer disease P3, P7, P397, P403, P408

Alzheimers disease P399

Alzheimer’s Disease 12, 42.2, P4, P154

AMPA receptors P306, P565, P569

Amphetamine P149, P717

Amygdala 7.4, 8.1, 21, 21.2, 21.4, 47, 47.2, 47.4, 55, 55.1, 55.2, P51, P62, P66, P85, P94, P104, P108, P120, P272, P291, P293, P307, P539, P630, P632, P654, P730, P736, P752

analgesia P460, P683

Anandamide P88

androgen deprivation 58.2

anhedonia 9.3, 52.3, P47, P176, P240, P244, P267, P330, P344, P356, P389, P478, P649

animal model 1, 1.3, 33.4, 48.1, P748

Animal Models 18.1, 31.2, 34.2, P176, P404, P698

anixety P478

anorexia nervosa P191, P192, P193, P195, P197, P200, P206

Anterior Cingulate Cortex (ACC) P389, P627, P678

Anterior insula P156

Anterior insula-prelimbic pathway P312

antibody P724

Antidepressant 52.2, P240, P298, P344, P355, P409

anti-depressant like action P361

Antidepressants P326, P354, P379

anti-gliadin antibodies (AGA) P546

antinociception P697

Antipsychotic 27.1, 53, P298, P489, P530

Antipsychotic drugs 51.2, P488

antipsychotic medication P350

Antipsychotic response P554

antipsychotics 27.3, 51.4, P212, P540, P561

Anxiety 30.3, 49, 52.1, P30, P34, P36, P42, P49, P55, P65, P70, P78, P81, P82, P83, P106, P126, P182, P262, P479, P605, P622, P654

Anxiety & PTSD 7.4, P40, P58

Anxiety and Depression 16.1, 27, 42, P130, P292

Anxiety and stress 31, P86, P725

Anxiety circuitry P86, P113

Anxiety development 38.2, 38.3

anxiety disorders P424

anxiety-like behavior P41

anxiety-like phenotype P23

anxiolytics P81

anxious distress P234

apathy 28

appetite regulation 39

Approach/Avoidance 40.1, P44, P263

arterial stiffness P93

Artifical transcription factors P218

associative learning 55.2

Astrocyte 35.1, P4, P211, P266, P500, P599, P612

Astrocyte-Blood vessel interaction P380

astrocyte-neuron interaction 35

astrocytes 18, 18.1, 35.2, P176, P215, P598

Attention P126, P167, P270

Attention Deficit Hyperactivity Disorder P433, P443

attention shifting P286

attentional bias P31, P55

Auditory fear conditioning 51.1, P63, P574

Auditory hallucinations 51.2, 51.3, 51.4

auditory perception 51, P574

Auditory striatum 51, 51.1, P574

Autism 5.3, 15.1, 33.1, 44, 44.1, 44.4, P109, P114, P116, P151, P439, P546

Autism & depression P433

autism spectrum disorder 33, 33.4, P166, P172, P179, P455, P569

Autism spectrum disorder and related syndromes 5, P129, P131

autism Spectrum Disorders P117, P150, P170, P174

Autoantibody P543

Autoimmune encephalitis P543

autonomic nervous system P57, P91

Autoradiography 27.1

aversion P265

Aversive Learning 56, 56.2, 56.3, P102

avoidance 56.1, P627

avoidant/restrictive food intake disorder P190

avolition 28, P504

Axon Initial Segment (AIS) P481

AXS-05 P227, P244

baclofen P159

Balb/c mouse P81

Bariatric Surgery P198

Basal forebrain P107

Basal Ganglia 31.2, P554, P744

basolateral amygdala 47.1, 55.3, P66, P107, P179, P381, P431, P468, P574, P663

BDNF P216, P445, P700

bed nucleus of stria terminalis P51, P84, P647

Behavior 36, P134

behavioral despair P213

behavioral economics P649, P699, P709

behavioral flexibility P105, P746

behavioral inhibition system P735

Behavioral Model 30, P201, P407

Behavioral Pharmacology 41.3, P86, P208, P368, P405, P458, P680

Behavioral Phenotyping P653

Behavioral Tasks P18, P433

Belief Updating P637

benzodiazepine P16

beta arrestin 2 P459

Biased signaling P601

big data P519

big data analysis P162

Binge alcohol use P607

binge drinking 50.3, P602, P641, P659, P702

Binge eating 39.3, P194, P469

Binge Eating Disorder 39, 39.3, P21, P204

Biobank P523

Biofeedback P57

Biology of aging P6, P13, P545

Biomarker P535, P611, P681

Biomarker analysis P299, P403, P436

biomarkers P320

Biomarkers for Risk Assessment 43.2

Biotypes P643

Bipolar Depression P247

Bipolar Disorder P120, P189, P217, P231, P234, P239, P254, P269, P270, P277, P283, P291, P293, P295, P303, P306, P310, P317, P329, P336, P339, P340, P353, P359, P364, P371, P482, P525

Bipolar I & II disorder P373

Bipolar I disorder P351

Blood vessel P215

Blood-Brain-Barrier P374, P666

BNST 25.3, P87, P622, P664

body dissatisfaction P199

Body Dysmorphic Disorder P415

body image disturbance P199

Body mass index P193

BOLD fMRI signal P277, P418, P631

Borderline Personality Disorder P469

Brain P206

Brain age P509

brain aging 24.3, P15

Brain Based Markers for Depression P402

Brain Circuits P20, P744

brain connectivity P207

brain connectome 5.4, P40

Brain development 42.1, P133

brain imaging P192

Brain Insulin Resistance 27, 27.1, 27.4

Brain Mapping P384

brain networks P209, P510

Brain nutrient sensing 27.3

brain proteomics P3

brain stimulation 8, 8.3, 19, P208

brain structure P302

brain transcriptomics P110

Brain-Based Predictive Modeling P499, P511

Brain-Behavior Relationships 30.4, 46

Brain-mediated mechanisms 27.3

breast cancer 58.3

bulimia nervosa P194

Buprenorphine P677

Buprenorphine-Naloxone P615

BXD mouse lines P253

Ca2+-permeable AMPA- type glutamate receptors P701

calbindin P483

calcium imaging P96, P216, P395, P421, P489

cAMP signalling P411, P561

canabinoid receptors P75

cancer 58, P296

cancer survival 58.2

Cannabidiol P174, P698

cannabinoid P705, P746

cannabinoid receptor type 1 P727

cannabinoids P683, P685

cannabis P145, P270, P586, P633, P650, P668, P683, P684

cannabis concentrates P684

cannabis use P295, P594

cannabis use disorder 26.3, P598, P683

capsulotomy 13.2

Cardiac Reactivity P310

Cardiometabolic Risk P69

cardiovascular P189

cardiovascular function P93

care coordination P677

cariprazine P83, P342, P343, P351

catecholamine 15.2

Caudate P123

Causal Modeling P43

CB1 receptor P90

CB2 receptor P560

CBT P276

Celecoxib P247

Cell adhesion molecules P652

Cell- and Circuit-selectivity P589, P639

central amygdala P595, P600, P721

central nucleus of the amygdala P318

cerebellum P550

Cerebral Blood Flow P156

Cerebral Cortex P744

cFos P369, P462, P659

c-Fos-expressing ensembles P753

CGRP P725

Chd1 33.1

Checklist 2

Chemobrain 58.2

chemogenetics 18.1, 44.4, P103, P151

chemokines P479

chemotherapy 58, 58.1

Child abuse and neglect P430

child and adolescent psychiatry P136

Childhood Adversity P11, P69, P651

childhood maltreatment P54, P636

Childhood trauma P46, P90, P145, P281, P321, P429

Childhood-onset schizophrenia P528, P529

Children and Adolescents P55, P143, P146, P171, P371

Cholesterol biosynthesis P4

choline P533

Cholinergic P434

cholinergic system P10, P596

chorea P398

choroid plexus 1.3, P23

CHRNA5 P655

Chronic corticosterone P268

Chronic diseases P327

chronic pain P59, P180, P688, P689, P715

Chronic social and non-social stress P253

chronic social defeat P373

chronic social defeat stress P112, P357

Chronic social stress P319, P380

chronic stress P211, P375, P391

Chronic unpredictable mild stress P376, P378

chronic unpredictable stress P222, P224

Chronic variable stress P221

chronotype P139, P482

cingulum P186

circadian rhythm P254, P401, P482

circadian rhythms P391

Circuit 47.2, 47.4

Circuit Development P292

circuit optogenetics P51, P111, P751

Circuitry-based approach 55.2, P659

Circulating cell-free mitochondrial DNA P223

claustrum 52.4, P21

Clinical Development P491

clinical efficacy P470

clinical high risk P498

clinical high risk for psychosis 43.3, P534, P549, P563, P576

Clinical high-risk of psychosis P509, P515

Clinical Neurobiology P457

clinical neuroimaging research 37, P308

clinical outcome prediction P193, P335

clinical prediction P287

Clinical predictors P346

clinical psychopharmacology P553

Clinical Subtypes P472

Clinical trial P25, P117, P119, P239, P400, P424, P494, P495, P614, P615

Clinical Trial Design 45, P450

Clinical Trial Methodology 8.2, P334

Clinical Trial Rating Methods P333

clinical trials P230

clinical trials methodology P28

Closed-Loop 8.3

Closed-loop control P94

Closed-loop stimulation P263

CNS Clinical Trials P298, P450, P491

cocaine 1.4, P611, P642, P663, P676, P701

cocaine addiction P592, P750, P752, P753

cocaine and opioid use disorders P584

cocaine self-administration P738, P747, P750

cocaine self-administration and reinstatement 55.3

cocaine sex differences P587, P716, P747

cocaine use disorder P443, P636, P644, P696, P706

Cognition 5.1, 18, 18.1, 24, 24.1, 24.4, 52.4, 53, P6, P124, P185, P246, P402, P408, P452, P496, P706, P712

Cognitive / behavioral flexibility P224, P500

cognitive and affective neuroscience 28

Cognitive biomarkers P229

cognitive control P501

Cognitive Control Cetwork P419

cognitive control network 21.2, 31.1

Cognitive Decline 24.2, 58.3

Cognitive dysfunction P571, P605

cognitive flexibility 7.1, P133

cognitive function P348, P532

Cognitive Functioning P499, P529

cognitive impairment 58, P222

Cognitive impairment associated with schizophrenia 24.3, 24.4, P503, P557

Cognitive impairments 24

Cognitive Impariment 14, 58.2, P503, P564

Cognitive Neuroscience 58.3, P43

cognitive reappraisal P53

Cognitive remediation P242

Cognitive test 24.2

cognitive training P119, P447, P452

Combat PTSD P27

Comorbidity P424

Co-morbidity P182

Complement component 4 P523

compulsive drug intake P610

Compulsivitiy P744

Computational Cognitive Neuroscience 30.2

computational ethology P330

Computational Genomics 35.3

Computational Methods P438, P514

computational modeling 3, 30.1, 30.3, 46, 56.1, P195, P284, P646

computational models of decision-making 16.4, P194

Computational Neuroscience 24.3, 30.4, P39, P513, P643

computational psychiatry 30.2, 30.3, 56.1, P56, P194, P287, P521

Concurrent Disorders P670

conditioned fear memory P377

conditioned inhibition of fear P96

conditioned place preference P592, P716

conflict of interest 4

Connectivity 21

Connectivity gradients P35, P100, P687

connectomics P446

consciousness P347

Consummatory behavior P702

Context P505, P733, P740

contextual fear P97

Continuous performance task P43

coordinated specialty care P551

COPD P581

copy number variants P110, P529

copy number variation P517

Correctional Psychiatry P670

cortex P668

cortical development P150

cortical plasticity 18.2

cortical thickness P54, P155

cortical thinning P121

Corticosteroids P14

corticosterone 34.1, P66

Cortico-striatal-thalamo-cortical Circuits 35.1

corticotropin releasing factor P609

Corticotropin-Releasing Hormone P94, P376

Cortisol P13, P38, P43, P311

Cortisol response to stress P245

COVID-19 38.3, 48.3, P91, P402, P503

COVID-19 pandemic P38, P58, P121, P262, P435

CpG Methylation P159

Craving 22.2, P182

c-reactive protein P544, P545

CRF P664

CRISPR 1.3

CROSS DISORDERS P188

CRP P72

CSF Biomarkers P13

Cue Reactivity 34, P614

cue-induced craving 26.2, P625, P634, P678, P688

cue-reactivity P621

Cytokine P247

cytokines P477, P546

cytoskeleton P489

D1 dopamine receptors 40.3

D2 dopamine and 5HT2A serotonin antagonists P356

D2 dopamine antagonists 27.1

D2 dopamine receptor P661

dACC P348

DBS 13.3, 31, 31.3, 31.4, P418

Decision Making 55.2, P195, P388, P390, P431, P468, P638, P712

deep brain stimulation 13, 13.1, 49, 49.4

Deep learning P439

Default mode network (DMN) 26.1, P258, P418, P576

defensive and motivated behaviors P107

delay discounting P441, P501

delta9-tetrahydrocannabinol P652

Delusions P521

Dementia 28

Dendritic spines 41.1

dentate gyrus P385

Depression 17, 27.4, 30.2, 30.3, 41.4, 42.2, 42.3, 52.4, P24, P60, P224, P230, P233, P245, P248, P250, P257, P260, P262, P274, P275, P276, P281, P294, P296, P297, P300, P308, P313, P316, P320, P322, P325, P326, P327, P328, P343, P345, P359, P368, P369, P372, P374, P375, P376, P380

Depression and Anxiety 30, P227

Depression model P204, P337, P366

Depression subtypes P228, P229

Derivative P366

Development 18.4, 49, P124

Developmental P122, P723

Developmental model P518

developmental origins 54, P8

Developmental Psychopathology 38.4, P128

Developmental Sensitive Period P133

developmental trajectories P154

Developmental trajectory P113, P115

Developmental transcriptome P153

diabetes P183

diagnosis P187

diffusion MRI 21.4

Diffusion Tensor Imaging (DTI) P567

diffusion tractography 31.4, P305

Diffusion Weighted Imaging P52

digital assessment 11, P167

Digital phenotyping 12, 16, 16.2, 16.4, P329, P333

digital psychiatry 42.3

digital therapeutic P129, P167

dimensional psychopathology P187

dimensions P187

dimensions of psychosis 7.3

dimethyltryptamine P425

discrimination 42.1

discriminative conditioning P96, P100

disinhibition P735

disorganization P512

Dissociation P352

diverse populations P416

Diversity P531

Diversity and Inclusion P169

DLPFC P272

DMT P425

DNA Methylation P54, P60, P77, P217, P301, P656

DOI P360

Dopamine 1.4, 7.3, 27, 27.2, 31.3, 40.3, 50.1, 50.2, 51, 51.1, 51.2, 51.3, 51.4, 55, 55.1, 55.2, 55.3, 56, 56.3, 56.4, 57.1, 57.2, P5, P19, P83, P105, P149, P203, P206, P207, P394, P432, P466, P542, P556, P559, P561, P574, P589, P593, P603, P609, P661, P687, P739, P740, P746, P748

Dopamine (D2, D3) receptors P356, P488

dopamine D2 receptors P561

dopamine D3 receptors P719

Dopamine D4 receptor P707

Dopamine function 55.4

Dopamine receptors P728

dopamine release P443

dopamine transporter 31.3

Dopaminergic neurons P489

Dopaminergic system 57

Dorsal anterior cingulate cortex P669

dorsal raphe P251

Dorsal striatum P203, P411, P590, P690, P738, P741

dorsolateral prefrontal cortex (DLPFC) P64, P153, P255, P534, P617

Dorsomedial striatum P573, P582

dose response P220

dose-response relations P323

DREADDs P583

drift diffusion model P286

drinking 50.2

drosophila 33

drowsiness P463

drug addiction P634

Drug choice paradigm P676

Drug Development P399, P704

Drug Discovery - new approaches P76, P363, P379, P503

drug discrimination 50.3, P691

Drug Poisonings 22.1

Drug Relapse 34.1, P606, P699

drug repurposing P439

Drug Seizures 22.1

drug self-administration P709, P735

drug targets P437

drug-drug interaction P709

Drug-naive P538

Dual orexin receptor antagonist (DORA) P615

Dual Orexin Receptor Antagonists P581, P696

Dynamic Causal Modeling P258, P415

dynamic functional connectivity P687

Dynorphin P21, P745

Dysphoria P24, P460

E/I imbalance P348

early brain development 38.2, P140

early childhood 5, 5.1

early improvement P342

Early intervention P552

early life 58.1

Early life adversity 14.3, P144, P434

early life anxiety P41

early life infection P155

Early life stress (ELS) P69, P111, P112, P115, P160, P161, P164, P177, P178, P385, P587, P663

early onset psychosis P122, P528

Early Parental Loss 40.4

Early Phase Drug Development P408

early psychosis 24.1, P305, P499, P501, P535, P536

early-life adversity 9.3, P9, P163, P318, P385

Early-life experience P142

eating behavior 39

Eating disorders 3, P190, P191, P194, P197, P202, P206

ecological momentary assessment P32, P35, P37, P168, P333, P451, P689

Ecological validity 46

Education and Training 20

EEG biomarkers 8, P130, P228, P252, P334, P450, P557

EEG connectivity P154, P267

EEG electrophysiology P352, P448

EEG/ERP electrophysiology P191, P274

Effective Connectivity P30, P415

Efference copy/corollary discharge P502

Efficacy and safety P226

effort based decision making task P389

Effort-Cost Decision-Making P620

electric field modeling P325

electroconvulsive therapy 17, 17.4, P266, P288, P325, P332, P382, P465

Electroencephalography (EEG) 43.1, P130, P169, P232, P267, P456, P502, P567, P570, P571, P572, P611

Electron Microscopy P548

Electronic cigarette (e-cigarette) P586, P722

Electronic Health Record 45

electrophysiology P220, P391, P485, P487, P706

elevated plus maze 52.1

EMA P284

Emergency Department P410

Emerging Therapies P399

Emotion Circuitry 9, P39, P97

Emotion Perception P291

Emotion regulation P248, P279

Emotional dysregulation P275, P469

Emotional empathy P430

Emotional regulation 21.1, P57, P271

Emotional stress P369, P628

Empathy P508

Emraclidine P566

endocannabinoid system P117, P188, P594, P747

Endocannabinoids 34.1, 47.3, 56, 56.4, P46, P50, P90, P380, P559, P626, P628, P715, P727, P732

energy metabolism P163

engram 47.3, P16

ENIGMA Working Group P519

enkephalin P251

Entropy P142

environmental risk factors 5, 29

epidemiology P152, P520

Epigenetic P401, P587

epigenetic age acceleration P11, P54

epigenetic clock P11

Epigenetic Modification 1, P595

epigenetic regulation P606

Epigenetics P1, P115, P213, P455, P592, P656, P657

epilepsy 33.1, P396, P406

Epitranscriptome P654

ERK P88

Escitalopram P247

esketamine 17.2, P237

Esketamine nasal spray P236

estradiol P68, P664

estrogen receptors P664

ethanol intake P700

ethical issues 4

ethics 36, 54

Ethnicity P531

excitation-inhibition balance P151

excitatory and inhibitory imbalance hypothesis 44.4

Excitatory Synapses P76, P422

executive function 30, 58.1, P652

exercise P1

exosome P223

exploration P432

exploration-exploitation tradeoff P432

explore-exploit dilemma P6, P284

Exposome P124, P164

Exposure therapy P25

Expression Polygenic Risk Score P300

extended-access self-administration P701

Extended-release naltrexone P616

Externalizing behavior 14.2

Extinction P87, P603

Extinction learning 41.1, P627

Extinction recall P29

extracellular matrix P211

Extracellular vesicles 15.1, 15.2

Extrapyramidal symptoms P351

extrasynaptic glutamate P220

eye tracking P170, P473, P679

eye-blink P463

F-18 PET Imaging 38.2, P12

Facial emotion processing 27.4, P55, P255, P456, P629

facial expression analysis P265

familial risk of bipolar disorder P371

family history of alcohol use disorder P658

family study 5.3

fast scan cyclic voltammetry P591

fatigue P281

Fatty acid amide hydrolase P304, P594

Fear P51, P87, P104, P108

Fear conditioning 7, 23, 47.1, P46, P78, P97, P100, P107, P369, P642

Fear conditioning and extinction 47.2, P85, P103

Fear extinction 41, P92

fear generalization 55.4

Fear learning 18.2

fear memory 9.4, 47

Fear Processing P415

fear-potentiated startle P36, P89

feeding 50.2

feeding behavior 50, P205

female 16.2

Fentanyl 22, 22.1, 22.2, 22.3, P583, P624, P640, P665, P692, P695, P709

fetal alcohol spectrum disorder P401

Fetal Brain Development 14.2, P477

fetal programming P148

FGF21 P375

FGF-21 P235

fiber photometry 56.3, P149

first episode psychosis P513, P551, P555

first-episode psychosis P550

Fluid homeostasis P17

fluorodeoxyglucose P442

fluoxetine P357

fMRI biomarkers 8, 16.1

fMRI Effective Connectivity P629

fMRI Functional Connectivity P32, P125, P293

focused ultrasound 13.3, P260, P365

food cues P190, P198

forced swim test P355

Forensic Psychiatry P670

formal thought disorder P512, P513

fragile X syndrome P159, P169

frequency optimization P322

frontopolar cortex P617

Frontostriatal P305

frontotemporal dementia P18

frustration P286

functional and structural neuroimaging 5, 58, P63

functional brain networks P124

functional connectivity P111, P200, P260, P554

functional data analysis P465

functional genomics P383

functional magnetic resonance spectroscopy P533

Functional MRI (fMRI) 8.1, 9.3, 26.3, 26.4, 38.1, 44.4, P6, P30, P45, P47, P48, P55, P65, P68, P99, P132, P143, P173, P190, P192, P248, P261, P384, P428, P430, P449, P454, P457, P504, P508, P614, P621, P623, P625, P627, P633, P644, P648, P661, P671, P678

functional neuroimaging 40.1, P157, P275, P280, P457, P494

G protein-coupled receptors P601

GABA P341, P474, P506

GABA MRS P506, P538

GABA neuron P106, P612

GABA-A P79

GABA-A receptors P324, P368

GABAergic interneurons 7.1

Gabapentin P703

galanin P445

gamma oscillation P570

gamma oscillations P365, P518

gamma, theta, delta P448, P464

Gamma-band auditory steady-state response (ASSR) P567

GDF-15 P235, P375

Gender P531

Gene co-expression networks 6.1, P297, P482

Gene environment interaction P164

gene expression 6, 58.1, P150, P471, P587

gene therapy P485

Gene-by-sex interaction P189

Gene-environment interaction P253

Generalizability P537

generalized anxiety disorder P39, P79, P99

Genetic Association Analyses P523

Genetic association study P156, P525, P653

genetic mouse model P72

Genetic Testing P528

Genetic variation P198, P436

Genetically encoded sensor P411

Genetics 33, P340

Genome-wide association studies P522

Genomics P188

geriatric P65

Ghrelin P614, P702

Glia 33.1

GLP-1 receptor agonist 39

Glucagon-like Peptide-1 39.1, 39.3

glucocorticoid receptor P222

glucocorticoid receptor gene P177

Glucocorticoid signaling P312

Glucocorticoids 34, P22, P266, P604

GluN2A recepter subunit P219

glutamate P64, P216, P278, P345, P353, P377, P458

glutamate GABA 43.1, 57.1

glutamate GABA co-release P273

glutamate transport P49

glutamatergic synapses P548

glutathione P283

glutathione (GSH) P353

glycine P213

glymphatic system P17

glyoxalase 1 P368

goal-directed behaviors 35.2, P745

Gonadal Hormones P619

GPCR P421, P562

GPCRs P427

GRAB-5HT P690

graph theory P138

Gray matter volumes P156

grid cell P7

grief 40.1

GRIN1 mutation P396

GRIN-related disorders P395

Group 2 Innate lymphoid cells P23

growth mixture modeling P313

Guidance cues 57.4

Guideline 2

Gut Microbiome 14.1, P147, P315, P316, P478, P667

Gut-Brain Axis P172

GWAS P416, P436, P441, P524, P532

habenula 49.2, P273, P596

Habenula and Periventricular Thalamus 49, 49.1

Habit P413, P738

habit formation P708

Habit Reversal Therapy P413

habituation 8.4

Hallucinations P521

hallucinogen P358

Headache P407

HEAL Initiative P674

Health Disparities P152

Healthy controls P667

heart rate variability P44, P93

heritability P199, P463

Heroin P599

heroin seeking P639

heroin self-administration P639, P711

High Density Sleep EEG P563

high fat diet P697

high-throughput screening P76, P114

hippocampal connectivity P387, P576

Hippocampal neurogenesis P210

Hippocampal volume P146

Hippocampal-prefrontal P37

Hippocampus 7, 7.4, P1, P35, P62, P108, P266, P297, P434, P448, P494, P516, P539, P619, P749

Hippocampus Shrinking P409

hippocampus-mPFC pathway P101

hIPSCs P22

Hispanic/Latinos 42, 42.2, P326, P651

histone deacetylases P455

histone variants 1.1

HIV P712

HIV and Inflammation P321, P586

HIV-Associated Neurocognitive Disorder P181, P185

HMGB1 P86

H-MRS P348

Hoarding Disorder P419

Homeostatic Plasticity 33.1

Homosexuality P578

hormonal contraceptive use P476

HPA axis 47.4

HPA axis dysregulation P312

hPSC 35.4

Human Clinical trial P26

human connectome P200

Human Genetics P440, P657

Human Laboratory Study P618

Human Neuroimaging 3, 8.2, 10, 19, 25.3, 40, 49, P40, P65, P145, P184, P189, P325, P455, P549, P620, P622, P637

human pluripotent stem cells P487

human postmortem brain tissue P110

Huntington’s Disease P398

Hyperarousal P126

hypothalamus 23.2, P196, P445

ibogaine P720

IGF-1 P114

IL-25 P23

Imaging P444, P556

imaging genetics P302, P440

Immune P320, P321

Immune Biomarkers P301, P547

immune function P72

immune markers P546

Immune responses P218

immune system 14.3, P471

immunity P8

Immunometabolism P544

immunotherapy P403

Impulsive behavior P208

impulsivity 30.1, P34, P125, P441

in vivo P461

in vivo calcium imaging 41.1, 51.2, 56.2, P98, P377, P743

in vivo electrophysiology 7.3

In vivo fiber photometry 47.3, 55, P19, P111, P179, P203, P363, P411, P593, P638

In vivo Imaging P379

incentive motivation P251

incentive salience 9.2, P658

incubation of cocaine craving P593

Incubation of drug craving 34, 34.2

incubation of oxycodone craving P590

Independent Component Analysis 16.2, P673

individual differences 9.2, P731

individual variation P635

Induced pluripotent stem cells (iPSCs) P484, P485, P527, P578

Infancy 5, 38.4

Infant Behavior 38, P186

Infant Brain 5.3, 38, 38.1, P186

Infant Emotionality 38, 38.3, P186

infant neuroimaging P140

inflammation 14.1, 14.2, P4, P50, P92, P217, P247, P322, P327, P370, P371, P544, P545, P564, P580, P665

Inflammatory Markers P274, P311

inhibition 30.1

Inhibitory control 57.4, P34, P128, P270, P419, P621

inhibitory interneuron 52.1, P585

Inhibitory interneurons 47.3

innovative methods P426

inpatient P308

insomnia P248, P581

Insula P147

insular cortex P21, P202

insulin 27, 27.2

insulin resistance P11

Intergenerational transmission of trauma P54

interleaved TMS/fMRI P272

Intermittent Access self-administration 1.4

internal capsule 13.1

internalizing disorders P32, P130, P138

interoception P191

interpeduncular nucleus P106, P596

intestinal microbiome P172

Intoxication P682

intracranial EEG P272, P448

intracranial self-stimulation P722

intravenous drug self-administration P583

intrinsic motivation P504

Intrusions P52

irritability 38.4, P286

IV- Ketamine 17.4, 31.1, P25, P230, P450

kappa agonist P460, P720

kappa opioid receptor P714, P745

Kappa Opioid Receptor Antagonist P240

KarXT P492, P493

Ketamine 31, P70, P246, P332, P337, P345, P357, P370, P379

Ketamine/esketamine 17, P288

Ketogenic diet P269, P697

Ketones P686

Kidneys P349

KINECT-HD2 P398

kratom P680

Kynurenic acid P503

kynurenine metabolism P579

Kynurenine pathway P546

Lactate-to-Pyruvate ratio P235

Language P326, P514

Laser Capture Microdissection P486

LASSI P181

Late-life Depression P223

Lateral Habenula 49.4, P201, P729

Learning 55, P104, P206, P271

learning and memory P433, P452

learning generalization P447, P641

Learning Health System P555

legislation 4

Lesions 13, P200

Levetiracetam P494

life-span 18

light-sheet microscopy P734

limbic system P664

Lipid metabolism P300

Lithium P349, P406

local field potentials P208

locomotor activity P716

loneliness P507

longitudinal P339

longitudinal multimodal imaging P41

longitudinal study 38.2, P186, P634, P648

long-term 17.2, P237, P343

long-term results 41.4

long-term safety 17

Loss 40, 40.3, 40.4

low-field MRI 43.3

LPS P12

LSD P459

LSD microdosing P347

lumateperone P231, P234

Lymphatics P17

M1 and M4 Muscarinic Receptors P493

machine learning P130, P161, P193, P232, P288, P306, P328, P332, P335, P537

machine learning classification P208, P330

Machine learning clustering P171, P256, P282, P289

Magnetic Resonance Imaging 9, P340, P509

magnetic resonance spectroscopy P64, P506

magnetoencephalography 43.4, P246, P258

Major depression P266, P333

Major Depressive Disorder (MDD) 21.2, 21.3, 49.4, P22, P210, P211, P214, P221, P225, P226, P227, P228, P231, P234, P237, P238, P240, P242, P243, P244, P249, P264, P267, P268, P285, P289, P295, P299, P304, P306, P307, P323, P331, P332, P334, P342, P343, P350, P355, P362, P373, P383, P423, P436, P547, P569

maladaptive feeding P201

marginalized youth P132

marmoset P518

Maronutrient P163

mast cells P70

Master Observational Trial 45

maternal behavior P163

maternal brain P430

Maternal Depression P473

maternal genotype P579

maternal immune activation 48.1, P148, P477

maternal mental health P140, P430

maternal stress P297

mating 23.2

Matrix Metalloproteinases P598

MC-100093 P700

MCH neurons P611

MDMA 41, 41.1, 41.2, 41.3, 41.4, P29, P456

mechanism 24, P220

Mechanistic Clinical Trial P248

medial entorhinal cortex P7

Medial Orbitofrontal Cortex 56

Medial Prefrontal Cortex 18.1, 34.1, 41.1, P100, P103, P105, P121, P133, P149, P259, P378, P395, P396, P602, P747

medio-dorsal thalamus P534

Medium Spiny Neuron P603, P748

MEG P466

mega-analysis P123

melanopsin P254

Memory 18.2, 42.2, P1, P8, P16, P35, P434

Memory and Learning P393, P461

Memory Bias P48, P641

Memory Enhancing P461

memory reconsolidation P752

Mendelian Randomization P524

Menstrual Cycle P474

Mental Health and Health Disparities 42, P171

Mental health disorders P152

Mesocorticolimbic system P127

mesolimbic circuitry 56.3

mesolimbic reward circuitry P314

meta-analysis P350, P533

Metabolism P134, P217

metabolomics P166, P315

metabotropic glutamate receptor P605

Metabotropic glutamate receptor 2 (mGluR2) P382

Methadone P685

methamphetamine 50, P347

Methamphetamine Self-Administration 50.1, P605

Methylation P657

methylone P26

methylphenidate P207, P687

mGlu5 P585

MIA 48

mice 7, P149, P388

mice imaging 44

Microbiome 14.2, 14.4, P166

Microbiota-gut-brain axis 14, P316

microcircuit processing 47.3

microglia 18, 18.3, 18.5, 25.2, 40.4, P73, P114, P176, P222, P318, P319, P517, P645, P662, P668, P718

MicroRNA P299

migraine P407

mild cognitive impairment due to AD P181, P242

Mild Traumatic Brain Injury P410, P442

mindfulness P74

miniscope P640

minocycline P552

miRNAs 15.2

mismatch negativity P95, P568

Misophonia P126

Mitochondria P2, P213, P223, P378, P409, P417, P575

mitochondrial DNA P417

mitochondrial DNA copy numbers P177, P373

mixed features P231, P234

Mobile technology 16.3, 42.3, P167

Model systems P393

moderators P32

Molecular Genetics P393

molecular mechanisms 15

Molecular profiling P169

Monetary reward P48, P184

Monoamine P366

monoclonal antibodies P608

Mood 31.3, 49

mood and anxiety disorders P358

mood disorder P362

mood disorders 9, 10, P58, P236, P273, P486

Moral distress 54

Morphine sensitivity P253, P697

mother-child dyads P33, P38

motivated behaviors P205

motivation 57.2, P271, P573, P740

Motor Evoked Potentials P541

motor learning P412

Mouse and monkey models P453

mouse brain 32, P465

Mouse Circuit Dissection 51

Mouse models P180, P391, P607, P668

mPFC P112, P464, P468

MR imaging P198, P519

MR spectroscopy P386

MRI P307, P423, P444, P516, P539, P742

MRSI 43.1, P554

Mu opioid receptor P251, P355, P582, P589, P693, P713

multi-echo fMRI P397

multimodal biomarkers 11

multimodal data 43

Multimodal Neuroimaging P289, P402, P536

Multimodality neuroimaging 43.4

Multi-omics P62, P319, P681

multiple sclerosis P392

multivariate pattern analysis P325

mu-opioid receptor agonist P704

muscarinic M4 P566

Muscarinic receptor agonist P492

Myelination 18.2

myo-inositol P533

N,N-Dimethyltryptamine (DMT) P80

N1 P502

N-acetylcysteine P353

nalfurafine P460, P714

nalmefene P714

naloxone 22, P692

Naltrexone P345

natural language processing (NLP) P328, P512, P513, P514

Natural setting 46

naturalistic drug cues P634

Navacaprant P240

Negative Affect P260, P506, P632, P647

negative reinforcement P19

Negative Symptoms 24.1, P122, P490, P491, P501, P508, P509, P544, P571

neighborhood resources P132

Neighborhood Socioeconomic Deprivation P146

network analysis P512

network based statistic (NBS) P636

network control theory P285

network neuroscience 43, 43.2, P30

Neural activity 32.3

Neural circuit and animal behavior 55.4, P390

neural circuits 31, P66, P98, P385

neural complexity P347

Neural connectivity 44.4, P262

Neural mechanism 53

neural plasticity P354

neural populations P577

neural progenitor cells 15.2

Neuroactive Steroids P474

neuroanatomy 39, 39.1, P440

neurobiological subtypes 44

neurocircuitry 21.4

Neurocircuits 13

Neurocognitive assessment 12, 30.2

neurocognitive function 58

neurodegeneration P394

Neurodegenerative Disease P17, P400

neurodegenerative diseases 11

neurodevelopment 43.3, P162, P529

neurodevelopmental and behavioral deficits P132

Neurodevelopmental Disorders 15, 15.1, 18.3, 56.1, P109, P118, P157

neuroeconomics P183, P388

Neuroendocrine P68

Neuroendocrine responses P134

neuroendocrinology P446, P476

neuroepigenetics 1.1

Neurofeedback P257

neurogenetics P485

neuroimaging P309, P372, P510, P535

neuroimaging biomarkers 16, 26, P379, P550

Neuroimmune 18.3, 25

neuroimmune activation P73

Neuroimmune communication 18.4, P70

neuroimmune mechanisms P662

neuroinflammation P12, P197, P586, P608, P700, P742

Neurokinin P730

Neurological and Psychiatric Disorders P405

Neuromelanin-sensitive MRI P5, P386, P537, P542

Neuromodulation 3, 8, 26.3, P200, P337, P397

neuronal culture P216

Neuronal ensembles P753

Neuronal Oscillations 8.3, P243

neuronal remodeling P222

Neuron-astrocyte interactions 35.1, 35.4, P49, P180

neuropathic pain P404

neuropeptide S P624

neuropeptides 23.2, P730

neurophysiology P324

Neuroplasticity 32.4, 52, P129, P233, P264, P365, P405, P409, P462

neuroprotection P15

Neuropsychiatric Disorders P560

Neuropsychiatric Disorders [Schizophrenia, Parkinson’s Disease, Major Depressive Disorder] P546

Neuropsychiatric symptoms (NPS) 29

neuropsychopharmacology P465

Neuropsychopharmacology (NPP) P368

Neuroscience 2

Neurosteroid P165, P475

neurosteroids 34, P337

Neurostimulation P255

neurosurgery for psychiatric disorders 13.2

neurotensin 50, 50.1, 50.2, 50.3, P601

neuroticism P125

Neurotoxicants 29

Neurotrophins P421

Neurovascular P374

Neurovasculature P215

new drug development P358

nicotine P591, P655, P689, P710, P722

nicotine addiction 1.3, P623, P673, P708

nicotine dependence 26.1

Nicotine exposure 1

nicotine withdrawal P673

nicotine/substance use disorder P613, P662

NINDS P674

NMDA Antagonists P219, P352

NMDA glutamate receptors P605

NMDA modulators P558

NMDA Receptor P220, P324, P395, P396, P543

NMDA Receptor Antagonist P227

N-methyl-D-aspartate P244

Nociceptin/orphanin FQ P695

nociception P715

non addictive analgesics P674

non pharmacological interventions P449

Non-hallucinogenic P361

Nonhuman Primate Models 38, 38.2, P41, P607

Non-human primates 21.4, P278

noninvasive brain stimulation 8.4, P243, P374, P617

Non-invasive Neuromodulation P225, P260

Nonlinear analysis P572

Non-opioid, Non-addictive Therapeutics P59

Noonan syndrome P158

noradrenaline P91

noradrenergic signaling P483

Noradrenergic System P618, P702

norepinephrine P5, P98

norepinephrine transporter P175

novel antidepressant P337

novel assessment tools for clinical trials P28

Novel coronavirus (SARS-CoV-2) P471

novel endpoints P75, P426

novel methods P331

novel object recognition P461

novel therapeutics P197

NPSR1 P624

NREM sleep P42, P579

Nucleus Accumbens 56.3, P84, P102, P205, P314, P378, P597, P598, P678, P730, P732, P746, P751

nucleus accumbens core P377, P561

Nucleus Accumbens Shell P251, P748

nucleus reuniens P178

nutrient sensing 27

Obesity 27.2, P11, P198, P449, P530, P545

Obesity and eating disorders 39.3, P204

observational fear learning P33

obsessive-compulsive disorder (OCD) 13.2, 13.3, 13.5, 31, 31.1, 31.4, 35, 56.2, P413, P414, P416, P417, P418, P420, P428

Obsessive-compulsive personality traits P414

OCD phenotypes 35.1

older adults P99

oligodendrocytes 18, 18.2, P392

omega-3 P552

Omega-3 Fatty Acid P118, P131

Open neuroscience P672

Operant behavior P468

opioid P345, P583, P718, P742

Opioid addiction P604, P628, P635, P637, P677, P685, P694, P724, P726, P734, P748

Opioid craving P711

opioid dependence 1, 1.3, P616, P748

opioid overdose P692, P724

opioid receptor P427, P699

opioid receptor expression P584

opioid receptor system P82

opioid reward P713

opioid side-effects P713

opioid tolerance P582, P733

Opioid treatment 22.2, P724

opioid use disorder 22.2, 26.4, P597, P613, P618, P665, P675, P727, P749

opioid withdrawal 22, P697, P698, P718

opioids 34.2, P680, P695, P703, P719

Opioid-sparing effects P685

optical biosensors P63

optical imaging P216

Optimism P637

optogenetics 31.2, 47.4, P98, P453, P734

Oral Self-Administration P640, P708

orbitofrontal cortex (OFC) 47.1, P431, P588, P590, P624, P634, P741

orexin P204, P696, P721

orexin receptor antagonist P675

orexin/hypocretin P84, P675

organic cation transporters P717

Organoids P484, P527

orphan receptors P561

Orthologs P221

outcomes P426

ovarian hormones P67, P587, P710

ovarian steriods P313

Overdose P749

oxidative stress P564, P575, P608

oxycodone P699

oxytocin 40.1, 41, 48.1, P82, P429, P694

PACAP P725

Pain P623, P685

pain models P580

Pain sensitivity P737

pair bond 40, 40.3, 40.4

Pallidum P442

pandemic P677

panic P71

parabrachial nucleus P647, P725

Parasympathetic nervous system 14.3

paraventricular nucleus of the hypothalamus P376

paraventricular nucleus of the thalamus 7.3, 9.2, 9.3, 9.4, P142, P290, P427, P751

paraventricular thalamus 7.2, 9, 49.2, P732

Parkinson’s disease P206, P394, P400

Partial agonist Ligands P707

parvalbumin P585

parvalbumin interneurons P133, P575

Parvalbumin neurons P518

patient centered research design P75

Patient Reported Outcomes 58.3, P336, P426

pattern separation P9

Pavlovian conditioning 55.3, P641, P690

PDE10A P553

pediatric 8.2, P412

Pediatric Bipolar Disorder P339

pediatric irritability P136

Perceived stress P261

Percieved control P261

periaqueductal grey (PAG) P103, P113, P737

Perimenopausal Depression P314

Perimenopause P314

perinatal depression P475

perinatal mental health P472

Perinatal stress P472

peripheral biomarker P13, P144

Peripheral blood marker P137, P214, P373

Peripheral neuromodulation P327

persistent avoidance P414

personalized medicine 16, 26, P245, P617, P643

PET Imaging P116, P214, P304, P453, P540, P569, P660, P661, P704, P728

PET Imaging Study P443, P565, P673

Pharmacodynamics P79

Pharmacogenetic Response P530, P681

pharmacogenomics P298

Pharmacokinetic and Pharmacodynamic P219, P365, P652, P686

pharmacokinetics P80, P425

Pharmacology P348, P363, P602

pharmacotherapy 1, 1.3, P748

Phase 1 P233

phase 1 study P352

Phase II clinical trial P228, P229, P245

Phase III trial P495

Phosphodiesterase-4 (PDE4) P12, P359

physical activity 42.2

Physical dependence P698

Physical exercise P15

Physician-Scientist 20

PKCdelta P600

placebo-controlled trial P476

placenta 15, 15.1, 15.2, P471, P477

plasticity 57.1

platelet derived growth factor P713

pleiotropy analysis P532

Polygenic risk for inflammation P155

polygenic risk score 6.1, P61, P154, P158, P164, P297, P302, P310, P340, P514, P522, P653, P658

polysubstance abuse P703

Positive Affect P633

positive allosteric modulators P79

Positive symptoms P563

positron emission tomography (PET) 25.2, P175, P423, P442, P466, P556, P566, P594, P645

post hoc analysis P342, P351

post treatment efficacy P616

Post-infectious Sequelae P58

Postmortem P526

Postmortem Brain Tissue 32, P60, P77, P438, P486

Postmortem Brain Tissue Gene Expression 6.1, P196, P480

Postmortem Human Brain Tissue 6, 35, P548

postpartum P378

postpartum depression P312, P470, P471, P472

Posttraumatic stress disorder 8.4, P27, P35, P37, P43, P74

poverty 14.2

prairie voles 33, P338

pre/post neuroimaging 19

Precision Imaging P303, P387

Precision Medicine 45

Precision Medicine for Depression 16.1

Precision Medicine for Mood Disorders 16.4, P336

precision psychiatry 17.4, 26, P228, P229, P309, P414

Preclinical P359, P560

Preclinical Alzheimer’s Disease 12

Preclinical models and endpoints P315, P461

Preclinical pharmacology P80, P219, P363, P407, P557

Predator Odor P691

Prediction P43, P261

Prediction error P47

Predictive Biomarker P170, P232

Predictive Coding P95, P513

Predictive Models 30.4

predictors of response 17.4

prefrontal cortex 43.1, 57.1, P14, P53, P62, P165, P224, P292, P548, P577, P585, P619, P639, P705, P736, P743

pregnancy 15, 15.1, 54, P89, P115, P118, P478, P479

premature treatment discontinuation P551

Prematurity P138

premenstrual dysphoric disorder P311, P474

Premorbid functioning 24.2

Prenatal alcohol exposure P648

prenatal anxiety 5.2

Prenatal Cannabis Exposure P134

Prenatal Drug Exposure 5.2, P145

Prenatal exposure 48, P8

Prenatal immune exposures 48.3

prenatal poverty 5.2

Prenatal SSRI Exposure P473

prenatal stress 5.2, 14.1, 48.3

Prenatal Stress Model 14.1, P131

prescribing P555

Prevention P242

primates P540

Prodromal Psychosis P497, P521

prodrome P498

progesterone P662

Pro-inflammatory cytokines 14, 14.4, P479

prolonged grief 40, 40.1

prophylactic P370

protective factors P498

Protein engineering 32.3

Proteomics 32, 32.3, 32.4, P109, P320, P524, P536, P588, P597

proton magnetic resonance spectroscopy P353

Proximity-labeling enzymes 32.3

Psilocybin 52, 52.3, 52.4, P346, P387, P400, P420, P459, P558

Psilocybin analog P226

PSPP P674

Psychedelic P405

Psychedelic effects P420, P457

Psychedelic medicine P95, P212, P328, P720

Psychedelic therapy 52, P176, P457, P558

Psychedelics 52.1, 52.2, P80, P238, P309, P315, P337, P358, P360, P362, P387, P400, P425, P459, P462, P711

psychiatric disorders P187

psychiatric genetics P416

psychiatric hospitalization P650

Psychiatric measurement 2

psychological distress P38

psychometric properties P281

psychometric tests P287

Psychoneuroimmunology P317, P321

psychopathology P118, P155, P187

Psychoplastogens P361

psychosis 51.2, 51.3, P3, P492, P498, P502, P505, P511, P522, P526, P537, P543, P552, P559, P564

Psychosis spectrum symptoms P122, P137, P515

Psychosis-Risk P482, P504, P516, P520, P552

Psychosocial Intervention P670

Psychosocial outcomes P536

Psychostimulant P424, P661, P723

psychostimulants P680

Psychotic Disorders P507

Psychotropic Medications P310

PTSD 7, 7.1, 7.2, 8.1, 9.4, 21.3, 23, 41, 41.2, 41.4, 47, P22, P24, P25, P26, P29, P33, P43, P45, P47, P50, P52, P60, P61, P64, P67, P72, P73, P77, P87, P89, P91, P92, P93, P598

puberty 57, 57.2, P127

publication policies 37

pulvinar P518

punishment P738

punishment learning 30.3, P750

pupil P463

pyramidal neuron P153

Quality control P162

quality of life 58.2, P227, P261, P677

Quantitative Electroencephalography (qEEG) P252

R-(-)-ketamine P370

Race P531

Race disparities 42.3, P61, P522

Racemic Ketamine and metabolites P726

racial ethnic minority 42

Racial minorities P296

Randomized Double-Blind P226

Randomized-Controlled Trial P118, P243

raphe P752

Rapid depression treatment P279

Rapid-acting Antidepressant 17, P238

Rare genetic variants P525

rat P722

Rats P458

Real World Data 45

real-time fMRI neurofeedback 21, 21.1, 21.2, 21.3, 21.4, P53, P135, P271

Real-world clinical outcomes 34.4, P555

reappraisal P99

receptor heteromerization P693

receptor tyrosine kinase P421

REDD1 (DDIT4, RTP801, Dig2) P224

Regeneration P392

Regulatory 2

Reinforcement learning 30, P591, P712

Reinforcement-based decision-making P644

relapse P87, P752

relapse biomarkers P285

relapse circuits 34.2

Reliability P384

REM sleep P85, P362, P579, P696

Renal P349

Renewal P603

repetitive behavior 35.1, P131

repetitive transcranial magnetic stimulation (rTMS) 13, 13.1, 13.4, 26, 26.1, 26.2, 26.3, 26.4, 43.4, P225, P232, P256, P282, P669

replicability 37

Replication P537

Research domain criteria (RDoC) P344, P536

Resilience 14.4, 32.4, P635

respiratory depression P692

response inhibition P141

Resting and task fMRI P160, P387, P454

resting state brain imaging P331

Resting State Connectivity 44, 44.1, P123, P502

Resting State Functional Connectivity 5.2, 5.4, 8.1, 9.3, 26.1, 49.1, 49.2, P27, P127, P142, P145, P290, P384, P414, P497, P511, P541, P550, P636

Resting state networks P565

Resting State, Functional MRI 49

Resting-state fMRI P37, P128, P151, P161, P207, P276, P613

retention 20

retrograde tracing P659

Reward P47, P207, P265, P273, P428, P476, P501, P633, P702, P739, P753

reward and aversion P427, P638

Reward Anticipation P690

reward circuitry P356

Reward functioning P135

reward learning P432, P731

Reward Liking P330

reward neural circuitry P262

reward prediction error P638

reward processing P31, P141, P376, P389, P648

Reward self-administration 50

Reward Sensitivity P127

Reward-based decision-making P646

Ribosome-heterogeneity P221

Risk P646

Risk and Resilience P498

Risk factors P520

risk genes 32

Risk Stratification 11

Risk-Based Decision-Making P364

Risky decision-making P268

RNA binding protein P393

RNA methylation P654

RNAseq 6, 35.4, P10, P151, P370, P394, P480, P486, P526, P583, P711

rsfMRI functional connectivity P565

rumination P280

safety learning P96

Safety/tolerability P470

Salience P202

Salience network P669

Schizophrenia (SCZ) 24, 24.2, 26.1, 27.3, 35, 35.3, 43, 43.2, 43.4, 51.4, P153, P359, P428, P480, P481, P484, P486, P487, P490, P492, P493, P494, P495, P496, P508, P509, P510, P514, P519, P523, P524, P525, P526, P527, P531, P532, P538, P540, P541, P543, P544, P545, P546, P547, P556, P561, P565, P566, P567, P569, P570, P571, P572, P573, P577

Schizophrenia novel treatment P553, P562

Schizophrenia Spectrum Illness 11, 14.4, 28, P520, P554

Schizophrenia subtypes P3, P546

School Environment P146

Selective Serotonin Reuptake Inhibitors (SSRIs) P63

self administration and CPP P674

Self-Administration 22, 22.3, P703, P717, P719

self-control P620

self-harm P478

Self-medication with psychedelics P95

semantic speech graph P512

Sensitive Period P113

sensitization 7

sensor technologies 46

Sensors 36

sensory processing 33.4, P412, P591

serious mental illness P650

Serotonin P63, P111, P259, P292, P385, P607, P690

serotonin 2A P362

Serotonin 5-HT2A Receptor P80, P212, P358

Serotonin 5-HT2C Receptor P175, P719, P729

sex and estrous cycle effects P584

sex differences 22.3, 25, 57.4, P8, P13, P16, P33, P50, P84, P103, P148, P150, P174, P178, P196, P211, P215, P275, P364, P434, P440, P511, P591, P596, P622, P626, P630, P635, P645, P676, P683, P691, P701

Sex-specific effects 25.3, P15, P180, P341, P422, P662

Sex-specificity P253

sexual orientation P578

Sexual trauma P296

Sibling design P172

Simulated Driving P682

Single nucleus RNA sequencing P62, P604

single-cell genomics P210

Single-cell RNA sequencing 1.4, 35.3, P301, P610

single-nuclei sequencing P734

single-nucleus RNA-seq P110

Single-unit electrophysiology ex vivo P427

Single-unit electrophysiology in vivo P18, P741

SK3 calcium-activated potassium channels P483

Skin conductance responses P33

sleep 42, 42.1, P329, P391, P580, P611

sleep architecture P581

sleep deprivation P85

Sleep disturbances P451, P665, P696

sleep spindles P42

slice electrophysiology P51, P354, P396, P582, P652, P732

slow oscillation P42

slow-wave activity P264

slow-wave sleep P85, P563

smartphone 16

Smartphone-based app 16.4, P413

SMS text messaging P326

SNAP25 P406

SNP P317

sociability P101

Social and behavioral deficits P338, P467

social anxiety P631

social anxiety disorder P28

social attachment 33.4, P467

Social Attention P473

Social Behavior 14, 23, 41, 41.2, 48.1, 56.1, P102, P174, P179, P218, P255, P390, P445, P456, P647, P672

social cognition 21.1, 24.4, P468

social cognitive skills training P129

Social Competence P464

Social defeat stress 57.4, P338

social deficits P144, P166

social determinants of health P146

Social determinants of health inequity 38.1, P171

social dominance P259

Social Drinking Motives P672

social fragmentation index P576

Social Functioning P508

Social hierarchy P736

social isolation 23.2, P500, P736

Social Isolation Stress P626

social jet lag P139

social motivation 40.3

social neuroscience 41.3

Social responsiveness P140

Social reward P48, P649

social stress 57, P84

Social support P435, P472

social-evaluative stress P630

software P438

solutions 37

Somatosensory processing P258

Somatostatin P408, P602

spatial memory P338

spatial multi omics P383

spatial representation P7

spatial transcriptomics P20, P196, P210, P383, P438

Spectroscopy P278

sphingosine 1-phosphate receptor P404

spinogenesis P76

Spontaneous Release P406

SSRI P120

State dependence 26.3

statistical methods P337, P438

Stimulants P173, P454, P719

Stress 25, 39.1, 47, 47.4, P23, P88, P168, P182, P209, P215, P372

Stress and Trauma P68, P91, P184

stress resilience P45, P259, P714

stress-enhanced fear learning (SEFL) 7.2

striatum 27.2, 31.3, P48, P104, P526, P609, P718, P739

Stroke P412

Structural MRI 43.3, 49.1, P120, P131, P134, P137, P147, P162, P256, P282, P289, P529

structural neuroimaging P158

Structural neuroplasticity P361

structure of psychopathology P128

subcortical volume 5.1

Subjective cognitive decline 12

Subjective Cognitive Impairment P682

Sugjective States P56

Substance abuse P648, P660

Substance abuse disorders 1, P653, P707

substance use P437

substance use disorder 1.5, 10, 26, 49, P601, P617, P636, P714, P728, P734, P743, P745

Substance-related disorders 26.2

Suicidal behavior 16.3

suicidal ideation 16.2, P168, P288, P451

Suicidal ideation and behavior assessment tool 16.3

suicide P168, P250, P258, P277, P284, P301, P302, P341, P435

Suicide attempt 21.1

Suicide Mechanisms P308

Suicide prediction P308

suicide prevention P279

sulforaphane P490

Surgery P2

Sustained remission P616

Synapses 32, P292, P546

synaptic density P116, P660

Synaptic Function P488

Synaptic Plasticity 35, 50.1, 52.2, P2, P76, P324, P377, P395, P421, P422, P585

Synaptogenesis 35.2

systems biology P109

systems neuroscience P446, P576

TAAR1 P495, P562

Tac2 23

Target engagement P119, P352

targeted cognitive training P496

task fMRI 30.4, P507

TCB-2 P360

telemetry P580

telescoping effect P701

telomere length P177

temperament 38.3

temperature regulation P163

temporal lobe P52

testosterone P127

Test-Retest Reliability P143, P280

Thalamo-cortical Interactions P577

Thalamus P539, P744

Thalamus - Reticular nucleus P178

THC P347, P682, P699, P712

theta burst transcranial magnetic stimulation P279

Theta-burst stimulation P36, P225, P255, P263, P671

Threat Conditioning P20, P44

Threat reactivity P68, P94, P98, P143

thymus P144

Thyroid P349

tianeptine P355, P409

TNF-alpha P700

Tobacco Smoking P594, P689

tolerance P212, P679

Toll-Like receptors (TLRs) P477

Tourette syndrome 31.2

Trajectories P294

Trajectory Modeling P43

trajectory of symptom improvement P323

Transcend Therapeutics P26

transcranial current stimulation P267

transcranial direct current stimulation (tDCS) 8.4, P27, P242, P447, P452

transcranial magnetic stimulation (TMS) 8.1, 8.2, 13.4, P24, P36, P263, P272, P323, P324, P374, P448, P571, P671

transcranial photobiomodulation P397

Transcriptome P663

Transcriptomics 1, P166, P209, P301, P549

transcutaneous auricular vagus nerve stimulation (taVNS) P322

Transdiagnostic P136

transgenic rat model P600

Translating Innovation P426

Translational Animal Models 3, 10, P268, P364

Translational biomarker approaches to drug development P238, P450

Translational Neuroscience 10

Translational Research 23

Translational studies P675

translocator protein (TSPO) 25.2, P214, P645

Trauma exposure P31, P43, P45, P74

Traumatic Memories P37

Traumatic stress P691

treatment 24, P556

treatment adherence P239

Treatment allocation P332

treatment duration P323

treatment outcome 19

treatment prediction 31.1

Treatment Resistant Depression 17.4, P219, P225, P249, P357, P386

treatment response P342, P550

Treatment-refractory depression P233

Treatment-resistant depression 17.2, P235, P237, P246, P256, P282, P289, P317, P346, P384

treatment-resistant schizophrenia P533, P542

Triazole P707

TSPO and [11C]PBR-28 PET P73

TWAS P657

twins P199

twin-study P463

Two-photon calcium imaging P363, P599, P624

Type 2 diabetes 27.3

Type I interferon signaling 18.4

Ulorant 53

Ulotaront P495

ultra high-risk youth P515

Ultra-high field MRI P257

Ultrasonic vocalization (USV) model P83, P640

ultrasonic vocalizations P144

Unbiased Effect Size Estimation P467

unpredictability P142

Vagus Nerve Stimulation P249, P327

valbenazine P398

Valence P104, P381

valporic acid P349

Valuation P56

Value-based Decision-Making P183, P192, P284

Vasopressin 1b antagonist P245

ventral hippocampus 7.1, 7.3, 52.1, P16

Ventral Pallidum 56.4, P381

Ventral Tegmental Area (VTA) 50.1, 55.3, P204, P257, P269, P604, P639, P721

ventrolateral prefrontal cortex P291, P293

ventromedial prefrontal cortex P96

vesicular glutamate transporter (VGLUT) P394

veterans P58, P294, P671

Vigilance P126

Viloxazine P175

viral tracing 39.1

virtual reality 8, 8.4, P24, P27, P31, P57

visual attention P505

visual perception P505

Visual Processing P95

vitamin D P443

Voltage-Gated Calcium Channel P483

voltammetry P609

Voxel-Based Morphometry (VBM) P475

Vulnerability P635

Waste clearance P17

Weight loss treatment P449

White Matter P52

White Matter Development 5.4, P41

White matter microstructural alteration P567

Whole exome sequencing P525

whole genome sequence P528

Whole-Brain Rodent Imaging 1.3, P388, P390, P659, P733

Williams syndrome P156, P157

withdrawal 1, 1.1, 1.3, 22.3, P748

women P93, P621

women’s health 54, P321

Women’s Mental Health P67

working memory P5, P14, P36, P119, P246, P428, P577, P706

World Trade Center Rescue and Recovery Work P45

Worry P30, P65, P99

xanomeline 53, P492, P493

Xylazine 22, 22.1, 22.3, P709

young adults P303, P633

youth P310, P497

Zaleplon P458

zebrafish 33

Zuranolone P470

α5 GABAA positive allosteric modulator P408

β-arrestin P212